Michael David Garrison Sells 597 Shares of Becton, Dickinson and Company (NYSE:BDX) Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael David Garrison sold 597 shares of Becton, Dickinson and Company stock in a transaction on Friday, January 17th. The shares were sold at an average price of $236.51, for a total value of $141,196.47. Following the sale, the executive vice president now directly owns 5,544 shares of the company’s stock, valued at $1,311,211.44. This represents a 9.72 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Michael David Garrison also recently made the following trade(s):

• On Thursday, December 19th, Michael David Garrison sold 2,838 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $223.33, for a total value of $633,810.54.

Becton, Dickinson and Company Trading Up 1.2 %

BDX stock traded up $2.74 during trading on Tuesday, hitting $240.12. 203,516 shares of the company traded hands, compared to its average volume of 1,985,530. The firm has a market capitalization of $69.64 billion, a PE ratio of 40.41, a P/E/G ratio of 1.72 and a beta of 0.39. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $248.42. The company has a 50-day moving average of $227.13 and a 200-day moving average of $232.70. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating the consensus estimate of $3.77 by $0.04. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. Becton, Dickinson and Company’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period in the prior year, the business posted $3.42 EPS. Analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th were issued a $1.04 dividend. The ex-dividend date was Monday, December 9th. This represents a $4.16 annualized dividend and a yield of 1.73%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 70.03%.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several institutional investors and hedge funds have recently bought and sold shares of BDX. Livelsberger Financial Advisory purchased a new stake in Becton, Dickinson and Company in the 3rd quarter worth approximately $26,000. Ashton Thomas Securities LLC purchased a new stake in Becton, Dickinson and Company in the 3rd quarter worth approximately $33,000. Tompkins Financial Corp raised its position in shares of Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 46 shares in the last quarter. Sound Income Strategies LLC raised its position in shares of Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 44 shares in the last quarter. Finally, Kennebec Savings Bank bought a new position in shares of Becton, Dickinson and Company in the 3rd quarter worth approximately $46,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

BDX has been the subject of several research analyst reports. Evercore ISI lifted their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Finally, Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Moderate Buy” and a consensus price target of $283.50.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.